Fc gamma receptor IIIb binding of individual antibody proteoforms resolved by affinity chromatography–mass spectrometry

Steffen Lippold, Alexander Knaupp, Arnoud H. de Ru, Rayman T. N. Tjokrodirjono, Peter A. van Veelen, Erwin van Puijenbroek, Steven W. de Taeye, Dietmar Reusch, Gestur Vidarsson, Manfred Wuhrer, Tilman Schlothauer, and David Falck

*Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands; †Pharma Research and Early Development, Roche Innovation Center, Munich, Germany; ‡Pharma Research and Early Development, Roche Innovation Center, Zurich, Switzerland; §Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Amsterdam Umc, University of Amsterdam, Amsterdam, The Netherlands; ‡Pharma Technical Development, Roche Innovation Center, Munich, Germany; ¶Biological Technologies, Genentech Inc, South San Francisco, USA

**ABSTRACT**

The crystallizable fragment (Fc) of immunoglobulin G (IgG) activates key immunological responses by interacting with Fc gamma receptors (FcγR). FcγRIIb contributes to neutrophil activation and is involved in antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These processes present important mechanisms of actions of therapeutic antibodies. The very low affinity of IgG toward FcγRIIb (K_D ~ 10 μM) is a technical challenge for interaction studies. Additionally, the interaction is strongly dependent on IgG glycosylation, a major contributor to proteoform heterogeneity. We developed an affinity chromatography–mass spectrometry (AC-MS) assay for analyzing IgG-FcγRIIib interactions in a proteoform-resolved manner. This proved to be well suited to study low-affinity interactions. The applicability and selectivity of the method were demonstrated on a panel of nine different IgG monoclonal antibodies (mAbs), including no-affinity, low-affinity and high-affinity Fc-engineered or glycoengineered mAbs. Thereby, we could reproduce reported affinity rankings of different IgG glycosylation features and IgG subclasses. Additional post-translational modifications (IgG1 Met252 oxidation, IgG3 hinge-region O-glycosylation) showed no effect on FcγRIIib binding. Interestingly, we observed indications of an effect of the variable domain sequence on the Fc-binding that deserves further attention. Our new AC-MS method is a powerful tool for expanding knowledge on structure–function relationships of the IgG-FcγRIIib interaction. Hence, this assay may substantially improve the efficiency of assessing critical quality attributes of therapeutic mAbs with respect to an important aspect of neutrophil activation.

**Introduction**

Immunoglobulin (Ig) G mediates key immunological responses by interacting with Fc gamma receptors (FcγR). FcγRIIb is found mainly on macrophages, natural killer cells and neutrophils, where it initiates various immune responses upon binding to opsonized IgG. The IgG-FcγRII interaction is strongly glycosylation-dependent. This is attributed to unique glycan–glycan and glycan–protein interactions between the receptor and the crystallizable fragment (Fc) of IgGs. Fcs with an afucosylated N-glycan show drastically increased FcγRII affinity. Increased affinity to activating FcγRs, such as FcγRII, results in increased cytotoxicity. Knowledge about the FcγR-IgG interaction enabled the rational design of anti-cancer monoclonal antibodies (mAb), glycoengineered for increased cytotoxicity.

FcγRIIb is a particularly interesting receptor because it is uniquely expressed in humans. Neutrophils, the most abundant phagocytes in the circulation, show high levels of FcγRIIb expression; in fact, the highest of any FcγR on any cell type. Neutrophils exert antibody-dependent cellular cytotoxicity (ADCC), as well as antibody-dependent cellular phagocytosis (ADCP). The neutrophil activation via FcγRIIib is considered an important mechanism of action of mAbs and is affected by the glycosylation, a critical quality attribute, of therapeutic mAbs. The extracellular domain of FcγRIIib is highly homologous to FcγRIIa (>97% sequence homology). However, FcγRIIb is the only FcγR lacking a transmembrane and cytosolic signaling domain and is, instead, anchored by glycosylphosphatidylinositol. Further, the IgG1 affinity of FcγRIIib (K_D ~ 10 μM) is up to ten-fold lower than for FcγRIIa (K_D ~ 1 μM), which was attributed to a single amino acid difference. Of note, the K_D values are highly dependent on the mAb glycoform. IgG subclass specificity of FcγRIIib interactions has been reported, with a higher affinity for IgG3 than IgG1 and no binding for IgG2 and IgG4. Three polymorphic variants of FcγRIIb, namely NA1, NA2 and SH, are known. The two most common variants, NA1 and NA2, differ in four amino acids, leading to four (Asn38, Asn74, Asn162, Asn169) or six (Asn38, Asn45, Asn64, Asn74, Asn162, Asn169) glycosylation sites for NA1 and NA2, respectively. For IgG1 binding, only minor differences were observed for NA1 and NA2.
In vitro measurements of monovalent affinity have been acknowledged as important metrics in mAb optimization. Of note, FcyRIIib affinity differences are difficult to measure with common techniques due to the low affinity and a high assay variability for FcyRIIib affinity assessments. Various studies have assessed the effect of mAb glycosylation on FcyRIIib affinity. Besides fucosylation, galactosylation or bisecting N-acetylglucosamine (bisection) were found to modulate the interaction as well, but to a smaller extent. The naturally occurring heterogeneity of mAb glycosylation (i.e., glycan features and glycan pairing) is a major challenge for linking affinity differences to specific glyco- or proteoforms in most assays.

We recently developed an affinity chromatography – mass spectrometry (AC-MS) platform for a glycoform-resolved FcyRIIIα binding assessment of mAbs. In contrast to AC-UV, individual glycoforms within a complex mixture could be analyzed in a single run by AC-MS, omitting the need for glycoengineering. Furthermore, AC-MS enabled unprecedented insights into typically low-abundant glycoforms, which have not been addressed by previous studies. The molecular resolution obtained by AC-MS is an outstanding advantage over established physicochemical techniques such as surface plasmon resonance (SPR). In addition, retention time shifts in AC were previously linked to differences in ADCC activities. This suggests that relevant approximations of the in vivo situation can be made by AC. Of note, physicochemical affinity assessment methods have high robustness and resolution. However, they do not fully reflect the in vivo complexity of biological interactions. Cell-based assays allow a better representation of the intricacies associated with immune complexes, at the expense of speed, robustness and resolution. Therefore, these approaches are highly complementary and usually go hand in hand in drug discovery efforts.

This study reports, for the first time, the use of an FcyRIIib affinity column for the binding assessment of mAbs. We developed the AC conditions for compatibility with MS and showed the glycoform-resolved affinity profiles of several classical and glycoengineered mAbs with high amounts of bisected and hybrid-type glycans. Furthermore, we demonstrated the selectivity of the FcyRIIib AC-MS toward different IgG subclasses.

**Materials and methods**

**Chemicals**

All chemicals were at least analytical grade and were purchased from Sigma-Aldrich (Steinheim, Germany), if not stated otherwise. A Purelab Ultra system (Veolia Water Technologies Netherlands B.V., Ede, Netherlands) system was used for deionized water. Mobile phases were prepared using an ammonium acetate solution (7.5 M) and glacial acetic acid (Fluka-Honeywell). First, a 1 M stock solution was prepared and further diluted to the target concentration. Proteases (GluC and chymotrypsin) were obtained from Worthington Biochemical Corp. (Lakewood, USA).

**Antibodies**

Nine different monoclonal antibodies (mAbs) were used in this study. mAb1, mAb3 and mAb4, as well as a Pro329Gly, Leu234Ala and Leu235Ala mutant (PGLALA) of mAb1, were provided by Roche (Penzberg, Germany and Zurich, Switzerland). mAb2 (anti-RhD, reported as +B) and anti-TNP subclasses (reported as IgG1*03, IgG2*01, IgG3*01, IgG4*03) were provided by Sanquin (Amsterdam, The Netherlands).

**Bottom-up liquid chromatography-MS/MS analysis**

FcyRIIib was subjected to in-gel digestion using GluC and chymotrypsin as reported previously. Digested FcyRIIib was subjected to bottom-up analysis by reversed-phase liquid chromatography (LC)-MS/MS. The separation of (glyco)peptides was performed on an Easy nLC 1200 system (Thermo Fisher Scientific) using a precolumn (15 mm × 100 μm; Reprosil-Pur C18-AQ 3 μm, Dr. Maisch, Ammerbuch, Germany) and an analytical nanoLC column (150 mm × 75 μm; Reprosil-Pur C18-AQ 3 μm). Mobile phase A was 0.1% formic acid in MQ. A gradient from 10% to 40% mobile phase B (0.1% formic acid/80% acetonitrile) was used for elution of (glyco-)peptides. The LC was hyphenated to an Orbitrap Exploris 480 mass spectrometer. MS1 scans were acquired in an m/z range of 400–3,500. The MS1 resolution was set to 120,000 (FcyRIIib). Data-dependent higher-energy C-trap dissociation (HCD) was used for MS/MS fragmentation. An isolation window of 1.2 Th and a resolution of 30,000 was applied. The charge states 2−7 (FcyRIIib) were included for fragmentation. For FcyRIIib analysis, HCD with normalized collision energy (NCE) of 30% was performed. In addition, triggered MS/MS (HexNAc loss (204.087)) was used applying stepped NCE of 20%, 30% and 50% combined to one spectrum in an m/z range 110–3,500.

**FcyRIIib glycopeptidomic data analysis**

The obtained (glyco-)peptide cleavage products were verified by automated MS/MS identification using Byonic (v. 3.7.13 Protein Metrics). Next, glycopeptide compositions for each glycosylation site were analyzed based on mass accuracies and retention time differences (MS² information) by GlycopeptideGraphMS. A glycan list covering all glycans from the different glycosylation sites was generated, then applied to each glycopeptide portion, integrated and manually checked based on retention time, mass accuracy (<10 ppm) and isotopic pattern quality (idotp > .85) in Skyline. Relative abundances were calculated based on the total area normalization for each glycosylation site.

**FcyRIIib column preparation**

The FcyRIIib affinity column was prepared as reported for FcyRIIIa AC. In short, human FcyRIIib NA1 was produced in HEK cells as a construct with C-terminal AviTag, IgA protease cleavage site (no cleavage was performed) and IgG Fc part (PGLALA mutant) as reported. The material was
then biotinylated and 3 mg receptor was immobilized on streptavidin sepharose beads and packed in a Tricorn column housing (5 mm x 50 mm, GE Healthcare). The column volume was 1 mL.

**FcyRIIIb affinity liquid chromatography–mass spectrometry**

FcyRIIIb affinity chromatography was performed using a biocompatible Thermo Ultimate3000 instrument (Thermo Fisher Scientific). For method development, UV detection at 280 nm and online pH monitoring (PCM-3000) were used. The system was operated at 20°C and with a flow rate of 0.5 mL/min. Mobile phase A (30 mM ammonium acetate, pH 6.8) and mobile phase B (50 mM acetic acid, pH 3.0) were used. All samples were buffer-exchanged to mobile phase A (30 kDa molecular weight cutoff filter, Merck, Darmstadt, Germany). 50 µg of the sample were injected for each run. Prior to injection, the column was conditioned for 30 min with mobile phase A. Upon injection, a washing step of 10 min mobile phase A was applied. Then, a linear gradient of 30 to 80% mobile phase B was used for elution. Next, an additional washing step with 80% mobile phase B for 10 min was used before returning to the starting conditions. The flow was split, diverting approximately 30 µL/min to the mass spectrometer. Online native MS detection was performed using a 15 T solariX Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (Bruker Daltonics, Bremen, Germany). MS settings were as described previously. Acquired spectra were manually inspected and visualized using DataAnalysis 5.0 (Bruker Daltonics). Deconvolution of mass spectra was performed using the Maximum Entropy tool with an instrument resolving power of 3,000. The deconvolution mass range was set from 145,000 to 155,000 Da. Proteoform assignment was performed manually on deconvoluted mass spectra using a mass tolerance of 50 ppm. The web-based Protein Tool (https://protpi.ch) was used for calculation of average masses considering the mAb sequence, C-terminal lysine clipping, glycosylation, disulfide bonds and N-terminal pyro-glutamine (if applicable). Extracted ion chromatograms were generated for charge states 22+ to 29+ in a window of ±0.4 Th.

**Results**

**Recombinant Fc gamma receptor glycosylation**

A human embryonic kidney (HEK) cell-produced FcyRIIIb (NA1) was used in this study. The NA1 variant of FcyRIIIb has four glycosylation sites (Asn38, Asn74, Asn162, Asn169). At least one peptide moiety for each glycosylation site was verified by MS/MS analysis (Figure S1–S4). A comprehensive site-specific analysis revealed 43 (Asn38), 56 (Asn74), 81 (Asn162) and 25 (Asn169) compositions at the individual sites, amounting to 95 different glycan compositions in total (Figure S5, Table S1). Asn162 glycosylation is visualized in more detail due to its functional importance (Figure 1). The relative abundance of aglycosylated Asn162 glycopeptide was negligible (0.1%). Furthermore, glycan compositions and structures of highly

![Figure 1](image-url). Asn162 glycosylation profiles of FcyRIIIb, comparing recombinant (HEK) and human neutrophil-derived receptor (the latter extracted from Wojcik et al). The data was normalized to the sum of all quantified compositions. For recombinant (HEK) FcyRIIIb, these are listed in Table S1. Glycan structures of selected compositions are suggested based on MS/MS experiments and previous findings on HEK cell-derived or human-derived neutrophil FcyRIII glycosylation. Asterisks (*) indicate that a glycopeptide was not detected.
abundant glycopeptides from recombinant (HEK) and previously reported human neutrophil-derived FcyRIIIb were compared (Figure 1).\textsuperscript{23}

**Fc gamma receptor IIIb affinity chromatography–mass spectrometry**

As mAbs have significantly lower affinity for FcyRIIIb than for FcyRIIIa, the separation was optimized starting from the previously reported conditions.\textsuperscript{18,20} Two mAbs were used for gradient optimization, representing either low afucosylation/low-affinity glycoforms (mAb1) or glycoengineered high afucosylation/high-affinity glycoforms (mAb3), respectively. A glycoengineered mAb with high levels of afucosylation showed up to seven-fold increased FcyRIIIb affinity compared to a mAb with a classical CHO-cell glycosylation profile, considering the average of all glycoforms.\textsuperscript{2} Therefore, the glycoengineered mAb used for method development (mAb3) was expected to show higher affinity glycoforms compared to mAb1. The fucosylated species showed no retention using reported FcyRIIIa AC-MS and AC-UV conditions (Figure S6). Sufficient binding of fucosylated species was achieved by lowering the ammonium acetate concentration to 30 mM (mobile phase A). Further, the pH was increased to 6.8 and the column temperature decreased to 20°C, facilitating retention of fucosylated species. A complete elution within the gradient was obtained by an acetic acid concentration of 50 mM in mobile phase B, which resulted in a final pH above 4 (Figure 2). For both mAbs, doubly fucosylated species could be chromatographically separated from singly and doubly afucosylated species. The charge state distribution of native MS spectra ([M + 22 H]\textsuperscript{22+} to [M + 29 H]\textsuperscript{29+}) did not change within the gradient. This indicates that the mAbs do not undergo large conformational changes under the applied separation conditions (Figure S7). An Fc-engineered version of mAb1 was used as a negative control to check for nonspecific interactions. This mAb1 version contained the Pro329Gly, Leu234Ala and Leu235Ala mutations, which abolish Fc receptor binding.\textsuperscript{28} None of the glycoforms showed any retention (Figure S8).

**Glycoform-resolved FcyRIIIb AC-MS of IgG1 mAbs**

Four different IgG1 mAbs, produced in Chinese hamster ovary (CHO) cells, were analyzed in a glycoform-resolved manner by FcyRIIIb AC-MS (Table S2, S3, Figure 3a-d). Of note, the constant part of the heavy chains of mAb1, mAb3 and mAb4 is based on the G1m17 allotype (mAb1 = G1m17, mAb3/4 = G1m17,1), whereas mAb3 is based on the G1m3 allotype. The constant part of the light chains of all four mAbs is based on the Km3 allotype.

Doubly fucosylated (GxF/GxF), singly afucosylated (Gx/F, Gx) and doubly afucosylated (M5/M5, Gx/Gx) species were resolved by FcyRIIIb AC-MS. The assigned glycoforms of mAb1, affinity ranking and inter-day retention time variability showed high similarity to previously reported FcyRIIIa AC-MS results (Table S3, Figure S9, Figure S10).\textsuperscript{18}

Next, the applicability of FcyRIIIb AC-MS to different glycoengineered mAbs (mAb2 - mAb4) was tested. Glycoforms of mAb2 were assigned mainly to fucosylated structures with varying levels of galactosylation and bisecting (Figure S11, Table S3). Both galactosylation and bisecting of mAb2 slightly increased retention in FcyRIIIb AC-MS. When comparing different IgG1 mAbs (Figure 2), the amino acid sequence apparently contributes to the retention. For example, the doubly fucosylated glycoforms (G0F/G0F, G1F/G0F, G1F/G1F) of mAb2 had increased retention compared to mAb1. In addition, the bisected fucosylated glycoforms of mAb2 (GxF/GxF, GxFN/GxFN) increased retention compared to mAb3. Of note, the assigned glycoforms showed a preferential pairing of bisected glycoforms (GxFN/GxFN) or non-bisected glycoforms (GxF/GxF), whereas hemi-bisected glycoforms (GxF/GxF) were not assigned. A minor amount of M5/M5 was detected and showed the highest retention time in mAb2 (Figure S11, Table S3).

mAbs glycoengineered via GlycoMab technology\textsuperscript{29} (mAb3 and mAb4) showed predominantly bisected, afucosylated glycoforms (Figure S12, S13, Table S3). mAb3 showed bisected glycoforms with different fucosylation levels (2x, 1x, 0x). For mAb4, no doubly fucosylated glycoforms and overall higher afucosylation were observed. In addition, glycoforms consisting only of the conserved pentasaccharide core and a bisecting N-acetylgalcosamine (G0N-N) were assigned, based on glycan data of the GlycoMab technology.\textsuperscript{29} The influence of galactosylation was more pronounced for mAb4 (e.g., ΔG0N/G0N vs. G1N/G0N) compared to mAb3. Low abundant high mannosyl (M5/M5) species showed the lowest retention of afucosylated glycoforms for both mAbs.

In addition, a singly oxidized (Met252) variant of mAb4 was subjected to FcyRIIIb AC-MS (Figure S14). Enrichment was achieved by neonatal Fc receptor (FcRn) chromatography as described previously.\textsuperscript{30} The glycoform masses of the oxidized version were in agreement with one additional oxidation. No notable influence of the oxidation on retention in FcyRIIIb AC-MS was observed (Figure S14).
**IgG subclass specificity of FcγRIIIB visualized by AC-MS**

We demonstrated that the reported IgG subclass specificity (IgG3 > IgG1, no retention of IgG2 and IgG4) of FcγRIIIB binding was reflected in the AC-MS approach. For this, a representative allotype of each of the four subclasses was analyzed. The different subclasses are referred to as IgG1 (G1m3; Km3), IgG2 (G2m( ); Km3), IgG3 (G3m(b’); Km3) and IgG4 (G4m(a); Km3). Similar glycosylation profiles and the same antigen-binding fragment (Fab) sequence (antitrinitrophenol (TNP)) allowed direct comparison of glycoforms (Figure 4a-d). Mainly, fucosylated complex-type glycans with varying levels of galactosylation (GxF/GxF) were observed. As expected, IgG2 and IgG4 did not show retention on FcγRIIIB AC (Figure 4b, d).

The doubly fucosylated glycoforms of IgG1 (G1m3; Km3) showed comparable retention to the same glycoforms in mAb1 (G1m17; Km3). In addition to this main peak (16–25 min; peak 2), a partially separated peak with reduced retention (7–16 min; peak 1) was observed (Figure 4a). The two peaks did not show a difference in the intact mass profiles (Figure S15). Both peaks were fractionated in triplicates, analyzed by tryptic bottom-up analysis and checked for deamidation levels in the Fc (data not shown). However, the bottom-up data were inconclusive to link the partial separation to a potential Fc deamidation site.

IgG3 showed a slightly higher affinity compared to IgG1, but a less pronounced increase in retention time for galactosylation (Figure 4a, c). In addition to the main IgG3 glycoforms (GxF/GxF), glycoforms with O-glycosylation (+1x H1N1S2 or +2x H1N1S2) were assigned (Figure S16). However, no noticeable influence on the FcγRIIIB affinity was observed for the IgG3 hinge O-glycosylation (Figure S17).

**Discussion**

**Receptor glycosylation**

FcγRIIIB glycosylation changes at Asn162 were reported to impact the interaction of FcγRIIIB with an IgG1 Fc fragment. Therefore, it is imperative to report both the antibody and the receptor glycosylation, in order to facilitate the comparison of results between different interaction studies. The recombinant FcγRIIIB glycan profile of Asn162 showed differences compared to recently reported natural FcγRIIIB glycosylation (Figure 1). Recombinant vs. natural FcγRIIIB showed higher levels of oligomannose forms (9.9% vs. 1.7%), lower levels of sialylation (average number of sialic acids per glycan 0.2 vs. 0.9) and LacDiNAc structures were exclusively present on recombinant FcγRIIIB. Furthermore, the amount of LacNAc units was less abundant in recombinant FcγRIIIB (Figure 1). FcγRIIIB from both sources showed antennary fucosylation (Figure 1, average number of fucoses per glycan 1.0 vs. 1.3). Interpreting the complex interplay between FcγRIIIB and antibody glycosylation remains challenging due to the scarcity of receptor glycosylation studies. Though we found glycosylation differences between recombinant and primary human FcγRs, there is as

**Figure 3.** FcγRIIIB AC-MS analysis of four IgG1 mAbs. A – D represent mAb1 to mAb4. Extracted ion chromatograms of glycoforms are displayed (Figure S9, S11 – S13, Table S3). Zoom in A visualizes low-abundant afucosylated glycoforms of mAb1. Some assigned minor glycoforms (< 5% relative to the main peak) of mAb2 – mAb4 are not displayed for visibility reasons.
yet no indication that this would affect the affinity ranking of different antibody glycoforms. Nonetheless, the observed differences in oligomannose forms may well affect the absolute affinity of the antibodies. In conclusion, as we only report affinity rankings of IgG glycoforms, the recombinant FcγRIIIb is expected to provide state-of-the-art information. If, in the future, the use of recombinant FcγR with more human-like glycosylation profiles would be attainable and desirable, our method offers the possibility to quickly adapt to the potential changes in affinity.

Specific advantages of affinity chromatography for low-affinity interactions

FcγRIIIb shows a very low affinity toward IgG1 (K_D ~ 10 μM) even when compared to other low-affinity FcγRs (FcγRIIa, FcγRIIa). For IgG1, a 10-fold lower affinity toward FcγRIIIb compared to FcγRIIa was reported. The low affinity of the receptor–antibody interaction was reported to lead to assay-to-assay variation for FcγRIIIb binding. A recent study applying SPR could not even determine binding affinities for different mAbs because the FcγRIIIb affinity was too weak. In our study, AC conditions reported for FcγRIIa showed insufficient retention for some glycoforms of the tested mAbs in FcγRIIIb AC. However, a generic FcγRIIIb AC gradient was developed with which both low- and high-affinity mAb glycoforms could be analyzed. A pH gradient alone was not sufficient to achieve this broad coverage. Because we had observed a stronger susceptibility of the FcγRIIIb interaction to the buffer concentration, compared to FcγRIIa, we successfully supplemented the pH gradient with a minor increase in buffer concentration. Of note, the pH gradient itself leads to a decrease in ionic strength. This likely counteracts the elution of antibodies, which is mitigated by increasing the buffer concentration with the gradient. This demonstrates one advantage of an AC-based assay for receptor antibody interaction studies. The chromatographic conditions offer much design space, while at the same time being tightly controlled. For example, different gradient parameters (ionic strength, pH) can be easily varied, and the temperature is more easily controlled in a flow than in a batch setup. Consequently, AC-MS assays can be both highly adaptable and robust. A significant presence of nonspecific binding, for example, through ionic interactions with the column material, was excluded using negative controls (mAb1 PGLALA variant, anti-TNP IgG2, anti-TNP IgG4). For different IgG1 mAbs and IgG subclasses, we could demonstrate that FcγRIIIb AC is a powerful and generic assay for assessing weak antibody–receptor interactions. It should be noted that the weak binding toward FcγRIIIb is expected to be less critical when studying multivalent interactions (avidity), i.e., of immune complexes, as opposed to monomeric mAb interactions (affinity). The affinity ranking of individual proteoforms is more insightful than solely K_D determination of proteoform mixtures by classical binding assays, such as SPR.
**Advantages of AC-MS for glycoform resolution**

The online hyphenation of FcγRIIIb AC to native MS allows comprehensive proteoform assessment of heterogeneous mAbs and can resolve subtle affinity differences. We demonstrated recently the advantages of FcγRIIIa AC-MS. In this and the previous study, mAb1 was comprehensively analyzed in a glycoform-resolved manner. The FcγRIIIb AC-MS glycoform affinity ranking and interday retention time stability of mAb1 showed high similarity compared to FcγRIIIa AC-MS (Figure S10).

Of note, the data are not directly comparable, due to the need to adapt the chromatographic conditions to the lower FcγRIIIb affinity. The level of fucosylation had the biggest effect on the FcγRIIIb affinity, which is attributed to a unique glyc–glycan interaction between antibody and receptor.

This is in line with other reports on FcγRIIIb-IgG interactions. We observed differences in the effect of galactosylation in the studied mAbs. Of note, galactosylation has recently been found to affect the hexamerization potential of IgG1, which may possibly increase avidity contributions to FcγR interactions. We found no indication that other multivalent interactions, such as aggregate formation exist in our analytical setup. Interestingly, the effect of galactosylation in glycoengineered mAbs was more pronounced for mAb4 than for mAb3 (G0N/G0N vs G1N/G0N). This may be related to different linkages of galactosylation (presence of terminal galactose on the 1,3-arm or the 1,6-arm), which show a positive (1,6) or no effect (1,3) on FcγRIIIa binding.

mAb2 showed the highest affinity of all doubly fucosylated and afucosylated (M5/M5) glycoforms (Table S3). A positive impact of the allotype can be excluded when comparing G0F/G0F of mAb2 with IgG1 (both G1m3; Km3). mAb2 was previously analyzed by FcγRIIIa AC-MS and the glycoforms showed increased RT as well when comparing to mAb1. However, the difference in FcγRIIIa affinity was not emphasized in the previous work. As similar FcγRIIIa binding profiles were reported, independent of the IgG1 allotype, the data hints to an influence of the variable domains on FcγRIII binding. This is in line with a recently demonstrated influence of the Fab on IgG1-FcγRIII receptor interaction. Although the Fab interaction sites were mainly attributed to the CH1 domain, amino acids within the variable domain were also found to contribute to the interaction. However, further studies using orthogonal techniques are needed to validate the observed inter-mAb FcγRIIIb differences. If a strong impact of the variable Fab domain on FcγRIII would be confirmed, this may have very important implications for modulating mAb effector functions.

The glycoengineered mAbs featured several unstudied pairings, for example, the combination of highly abundant G0N with oligomannose (G0N/M5) or bisected mono-antennary (G0N/G0N-N) glycoforms. Their investigation would require laborious glycoengineering, reducing, but not even fully eliminating, the heterogeneity of the mAb glycoform profiles. This highlights the advantage of FcγRIIIb AC-MS for affinity ranking of individual proteoforms. Here, we described the analysis of (therapeutic) mAbs produced in CHO or HEK cells, which are widely used production systems. Potential glycosylation differences in human IgG antibodies are extensively discussed in the literature. The developed method is expected to apply to the majority of therapeutic mAbs. However, it should be noted that the proteoform resolution may be highly impaired for mAbs with additional complexity besides Fc glycosylation, e.g., Fab glycosylation. These may require additional method development as shown for the analysis of cetuximab by FcγRIIIa AC-MS. Finally, it should be stressed that the developed assay targets qualitative differences between glycoforms. More precise insights may be obtained by comparing retention time differences in AC-MS to quantitative data of highly homogeneous glycoengineered mAbs or fractions obtained by AC-MS.

**Affinity impact of additional post-translational modifications**

Moreover, the glycoform-resolution obtained by FcγRIIIb AC-MS allowed study of the affinity impact of post-translational modifications (PTMs), other than Fc N-glycosylation.

We concluded that oxidation at Met252 is not critical for FcγRIIIb binding (mAb4, Figure S14). In contrast, FcRn and FcγRIIa binding have been reported to be decreased in the presence of Met252 oxidation. These differences with respect to Fc receptor binding are in line with the proximity to the different binding sites. In conclusion, we could demonstrate that AC-MS allowed the analysis of specifically enriched oxidized mAb variants for FcγRIIIb binding differences. Of note, PTMs cannot be located by intact mass analysis alone, and the co-occurrence of multiple PTMs may hamper the data interpretation.

The partial separation of IgG1 glycoforms (Figure 4a) was hypothesized to be related to Asn deamidation in the Fc. Increased Asn325 deamidation levels were previously reported to reduce FcγRIIa binding. However, additional experiments were inconclusive in supporting this interpretation. Partially reduced or scrambled disulfide bonds are another potential PTM, which is not resolved by intact mass analysis. This modification was also shown to affect FcγRIIa binding. Additional experiments would be needed to pinpoint the modification responsible for the additional separation of IgG1 proteoforms.

In contrast to the other IgG subclasses, some IgG3 allotypes additionally contain O-glycans. We could demonstrate the feasibility of measuring intact IgG3 with FcγRIIIb AC-MS. For the first time, we showed that the hinge O-glycosylation of IgG3 does not significantly influence the FcγRIIIb affinity. Moreover, the affinity of IgG3 was found to be slightly higher compared to IgG1, which is in line with recent findings. IgG3-based biopharmaceuticals are not yet on the market, but the first clinical trials were recently started. Despite its disadvantages, IgG3 has several benefits and may be reconsidered for biopharmaceutical applications in the future. This makes a proteoform-resolved method for Fc receptor affinity assessments highly desirable.

The combination of FcγRIIIb AC and MS is very powerful to unravel complex glycosylated antibodies. It allows unprecedented molecular insights into the relative affinity ranking of unstudied glycoform pairings. We demonstrated the applicability to different (glycoengineered) mAbs. In addition, our data show the potential of AC-MS-based affinity assessments to simultaneously study the impact of different forms of post-translational modifications. All of this makes the method attractive for supporting the assessment of critical quality attributes.
Importance of understanding FcγRIIIb-mediated effector functions

The role of FcγRIIIb binding is less studied and understood compared to FcγRIIa. Whereas the FcγRIIa affinity of mAbs positively correlates with natural killer cell-mediated ADCC, recent studies demonstrated that glycoengineered/high-affinity mAbs increased ADCP, whereas ADCC was impaired. In this context, it is debated whether FcγRIIIb supports or hinders the FcγRIIa mediated activation of neutrophils. There is also evidence that FcγRIIIb by itself can lead to neutrophil activation. Therefore, it is important to be aware of the relative expression levels and affinity of mAb proteoforms toward FcγRIIb and FcγRIIa. This could be crucial in understanding which neutrophil effector functions are activated by a therapeutic mAb. In addition, the use of high FcγRIII-affinity mAbs has been linked to safety concerns due to first infusion reactions, mediated by neutrophil FcγRIIIb. Since FcγRIIIb is uniquely present in humans, these effects cannot be assessed by animal-based preclinical studies. In conclusion, an analytical platform for differentiating FcγRIIабilities of mAb proteoforms, as presented in this study, is of high relevance to better understand and predict the safety and efficacy of therapeutic mAbs.

Abbreviations

ACA Affinity chromatography
ADCC Antibody-dependent cellular cytotoxicity
ADCP Antibody-dependent cellular phagocytosis
CH Constant domain heavy chain
CHO Chinese hamster ovary
Fab Fragment antigen binding
Fc Fragment crystallizable
FcγRγC gamma receptor
FcRn Neonatal Fc receptor
FT-ICR Fourier transform ion cyclotron resonance
HCD Higher-energy C-trap dissociation
HEK Human embryonic kidney
Ig Glycoprotein
LCL Liquid chromatography
mAb Monoclonal antibody
MSM Mass spectrometry
NCEN Normalized collision energy
PTM Post-translational modification
SPR Surface-plasmon resonance
UVU Ultraviolet

Acknowledgments

This research was supported by the Roche/Genentech Global Strategy Team (GST). David Falck received funding from the Dutch Research Council (NWO) in the framework of the ENW PPP Fund for the top sectors (project Proteoform-resolved pharmacokinetics of biopharmaceuticals, no. 019.012). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No [765502], A4B project.

Disclosure statement

Alexander Knaupp, Erwin van Puijenbroek, Dietmar Reusch and Tilman Schlotherau are employees of Roche/Genentech, the manufacturer of the column and the therapeutic antibodies used in this research.

Funding

This research was supported by the Roche/Genentech Global Strategy Team (GST). David Falck received funding from the Dutch Research Council (NWO) in the framework of the ENW PPP Fund for the top sectors (project Proteoform-resolved pharmacokinetics of biopharmaceuticals, no. 019.012).

ORCID

Steffen Lippold http://orcid.org/0000-0002-1032-5808
Gestur Vidarsson http://orcid.org/0000-0001-5621-003X
Manfred Wuhrer http://orcid.org/0000-0002-0814-4995
David Falck http://orcid.org/0000-0003-3908-2376

References

1. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34–47. doi:10.1038/nri2206. PMID: 18064051.
2. Dekkers G, Treffers L, Plomp R, Bentlage AEH, De Boer M, Koeleneer CAM, Lissenberg-Thunnissen SN, Visser R, Brouwer M, Mok JY. Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of fc-receptor- and complement-mediated-effector activities. Front Immunol. 2017;8(877). doi:10.3389/fimmu.2017.00877. PMID: 28824618.
3. Ferrara C, Grau S, Jäger C, Sondermann P, Brinker P, Waldhauer I, Henning M, Ruf A, Rufer AC, Stihle M. Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγR and antibodies lacking core fucose. Proc Natl Acad Sci U S A. 2011;108(31):12669–74. doi:10.1073/pnas.1104551108. PMID: 21768335.
4. Radaev S, Motyka S, Fridman W-H, Sautes-Fridman C, Sun PD. The structure of a human type III Fcγ receptor in complex with Fc. J Biol Chem. 2001;276(19):16469–77. doi:10.1074/jbc.M100350200. PMID: 11297532.
5. Barb AW. Fcγ receptor compositional heterogeneity: considerations for immunotherapy development. J Biol Chem. 2021;296:100057. PMID: 33172893. doi:10.1074/jbc.REV120.013168.
6. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8(3):226–34. doi:10.1038/nrd2804. PMID: 19247305.
7. Kerntke C, Nimmerjahn F, Riburger M. There is (scientific) strength in numbers: a comprehensive quantitation of Fc gamma receptor numbers on human and murine peripheral blood leukocytes. Front Immunol. 2020;11(118). doi:10.3389/fimmu.2020.001118. PMID: 32117269.
8. Golay J, Da Roit F, Bologna I, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122(20):3482–91. doi:10.1182/blood-2013-05-504043. PMID: 24106207.
9. Subedi GP, Barb AW. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fcγ receptor. mAbs. 2016;8(8):1512–24. doi:10.1080/19420862.2016.1218586. PMID: 27492264.
10. Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25(12):1325–34. doi:10.1093/glycob/cwv065. PMID: 26263923.
11. Alt N, Zhang TY, Motchkin P, Tatischek R, Quarovy V, Schlotherau T, Beck H, Emrich T, Harris RJ. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals. 2016;44(5):291–305. doi:10.1016/j.biologicals.2016.06.005. PMID: 27461239.
12. Roberts JT, Barb AW. A single amino acid distorts the Fcγ receptor IIIb/CD16 structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a. J Biol Chem. 2018;293(51):19899–908. doi:10.1074/jbc.RA118.005273. PMID: 30361439.
of symmetrically and asymmetrically modified antibodies. mAbs. 2019;11(6):1101–12. doi:10.1080/19420862.2019.1618675. PMID: 31161859.

42. Lu X, Machiesky LA, De Mel N, Du Q, Xu W, Washabaugh M, Jiang X-R, Wang J. Characterization of IgG1 Fc deamidation at asparagine 325 and its impact on antibody-dependent cell-mediated cytotoxicity and FcγRIIIa binding. Sci Rep. 2020;10(1):383. doi:10.1038/s41598-019-57184-2. PMID: 31941950.

43. Bahou C, Love EA, Leonard S, Spears RJ, Maruani A, Armour K, Baker JR, Chudasama V. Disulfide modified IgG1: an investigation of biophysical profile and clinically relevant Fc interactions. Bioconjug Chem. 2019;30(4):1048–54. doi:10.1021/acs.bioconjug.chem.9b00174. PMID: 30855134.

44. Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal U, Desjarlais JR, Humpe A, Valerius T, Peipp M. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. mAbs. 2014;6(2):409–21. doi:10.4161/mabs.27457. PMID: 24492248.

45. Treffers LW, van Houdt M, Bruggeman CW, Heinke MH, Zhao XW, van der Heijden J, Nagelkerke SQ, Verkuijlen PJH, Geissler J, Lissenberg-Thunnissen S. FcγRIIib restricts antibody-dependent destruction of cancer cells by human neutrophils. Front Immunol. 2019;9:3124–3124. PMID: 30761158. doi:10.3389/fimmu.2018.03124.

46. García-Garcia E, Nieto-Castañeda G, Ruiz-Saldaña M, Mora N, Rosales C. FcγRIIA and FcγRIIIB mediate nuclear factor activation through separate signaling pathways in human neutrophils. Journal of Immunology (Baltimore, Md: 1950). 2009;182(8):4547–56. doi:10.4049/jimmunol.0801468. PMID: 19342628.

47. Guilliams M, Bruhns P, Saey Y, Hammad H, Lambrecht BN. The function of Fcy receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14(2):94–108. doi:10.1038/nri3582. PMID: 24445665.

48. Weber F, Breustedt D, Schlicht S, Meyer CA, Niewoehner J, Ebeling M, Freskgard PO, Bruenker P, Singer T, Reth M. First infusion reactions are mediated by FcγRIIib and neutrophils. Pharm Res. 2018 Jun 27;35(9):169. doi:10.1007/s11095-018-2448-8. PMID: 29951887; PubMed Central PMCID: PMCPMC6021477.